Drug Research
Sanofi launches dedicated vaccines mRNA Center of Excellence
Sanofi will invest approximately €400 million annually in a first-of-its kind vaccines mRNA Center of Excellence. The Center will work to accelerate the development and delivery of next-generation vaccines by bringing together approximately 400 dedicated employees integrating end-to-end mRNA...
Drug Research
Roches Actemra/RoActemra receives U.S. FDA EUA for the treatment of COVID-19 in hospitalised adults and children
Roche announced that the U.S. FDA has issued an EUA for intravenous Actemra/RoActemra® (tocilizumab) for the treatment of COVID-19 in hospitalised adults and paediatric patients (two years of age and older) who are receiving systemic corticosteroids and require supplemental...
Drug Research
Fujitsu Japan Embarks on Joint Research for COVID-19 Therapies Using Fugaku
Fujitsu Japan Limited announced that it will initiate a new research project with a research team led by Takefumi Yamashita, Project Associate Professor of Research Center for Advanced Science and Technology (RCAST) , the University of Tokyo utilizing the...
Drug Research
Coriolis Pharma Expands ATMP Development Facilities
Coriolis Pharma, a provider of research and development of for (bio)pharmaceutical drugs, is expanding its advanced therapy medicinal products (ATMP) development facilities under biosafety level S2 (BSL2 / S2).
Re-construction of an existing building near the Coriolis headquarters started in...
Drug Research
UNC researchers develop potential universal coronavirus vaccine
Scientists at the University of North Carolina Gillings School of Global Public Health have developed a universal vaccine that protected mice not just against COVID-19 but also other coronaviruses and triggered the immune system to fight off a dangerous...
Drug Research
mCureX and Samyang sign MoU for mRNA vaccine development
OliX Pharmaceuticals’ subsidiary mCureX has entered a memorandum of understanding (MoU) with Samyang Holdings to develop a messenger ribonucleic acid (mRNA) vaccine for Covid-19.
The companies are co-developing a vaccine that could potentially target Covid-19 viral variants.
According to the deal,...
Drug Research
AGC Biologics Heidelberg Facility to Further Supply Plasmid DNA for COVID-19 Vaccine
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced its partnership with BioNTech SE to further supply Plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine, at AGC’s Heidelberg, Germany facility.
“We are honored...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
